Tirosina Quinase/Adaptador
Os inibidores de tirosina quinase e adaptadores são compostos que têm como alvo as tirosina quinases e suas proteínas adaptadoras associadas, que desempenham papéis fundamentais na sinalização celular, crescimento e diferenciação. Esses inibidores são ferramentas essenciais na pesquisa sobre o câncer, pois muitas tirosina quinases estão envolvidas nas vias de sinalização que impulsionam o crescimento e a metástase dos tumores. Ao inibir as tirosina quinases, esses compostos podem bloquear cascatas de sinalização críticas, oferecendo potenciais estratégias terapêuticas para vários tipos de câncer e outras doenças que envolvem sinalização celular anormal. Na CymitQuimica, oferecemos uma ampla gama de inibidores de tirosina quinase e adaptadores de alta qualidade para apoiar sua pesquisa em oncologia, biologia molecular e desenvolvimento de terapias direcionadas.
Subcategorias de "Tirosina Quinase/Adaptador"
- ALK(112 produtos)
- CSF-1R(42 produtos)
- EGFR(572 produtos)
- Receptor de Efrina(23 produtos)
- FLT(93 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(169 produtos)
- HER(5 produtos)
- Hck(3 produtos)
- IGF-1R(87 produtos)
- PDGFR(126 produtos)
- PYK2(7 produtos)
- Src(79 produtos)
- Receptor TAM(32 produtos)
- Tie-2(20 produtos)
- Receptor TrK(59 produtos)
- Tirosina Quinases(26 produtos)
- VEGFR(268 produtos)
- c-Fms(108 produtos)
- c-Kit(101 produtos)
- c-Met/HGFR(128 produtos)
- c-RET(51 produtos)
Exibir 13 mais subcategorias
Foram encontrados 1372 produtos de "Tirosina Quinase/Adaptador"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
(Rac)-SAR131675
CAS:<p>(Rac)-SAR131675 is an effective and specific VEGFR-3 inhibitor, which inhibited VEGFR-3 tyrosine kinase activity and VEGFR-3 autophosphorylation in HEK cells.</p>Fórmula:C18H22N4O4Pureza:98.34% - 99.1%Cor e Forma:SolidPeso molecular:358.39Serclutamab
CAS:<p>Serclutamab, a humanized chimeric monoclonal antibody of the IgG1-κ isotype, selectively targets the epidermal growth factor receptor (EGFR).</p>Pureza:98%Cor e Forma:LiquidFrunevetmab
CAS:<p>Frunevetmab (NV-02) is a feline-adapted monoclonal antibody targeting NGF (nerve growth factor), with a Kd value of 20 pM. Feline osteoarthritis (OA).</p>Pureza:95% - 95%Cor e Forma:LiquidElgemtumab
CAS:<p>Elgemtumab (LJM716) is a fully humanised monoclonal antibody targeting HER3/ERBB3, acting as an antagonist to block HER3/Akt phosphorylation antitumour.</p>Pureza:95%Cor e Forma:LiquidFulranumab
CAS:<p>Fulranumab (AMG-403) is a humanised monoclonal antibody targeting NGF, analgesic effects, and can be used for the study of chronic pain.</p>Pureza:95%Cor e Forma:LiquidBarzolvolimab
CAS:<p>Barzolvolimab (CDX 0159), a humanized IgG1 monoclonal antibody, blocks KIT activation and treats chronic urticaria.</p>Cor e Forma:LiquidDavutamig
CAS:<p>Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.</p>Pureza:98%Cor e Forma:LiquidAnti-IGFBP2 Antibody (M14)
<p>Anti-IGFBP2 Antibody (M14) is a human monoclonal antibody inhibitor that binds with high affinity to IGFBP2 and prevents its interaction with IGF1. Additionally, Anti-IGFBP2 Antibody (M14) can inhibit the recruitment of human endothelial cells, thereby obstructing tumor progression in human metastatic cancers.</p>Cor e Forma:Odour LiquidPonezumab
CAS:<p>Ponezumab (PF-04360365), a humanized IgG2 antibody, lowers Aβ in the CNS & boosts mice memory. Used in Alzheimer's research.</p>Cor e Forma:LiquidFutuximab
CAS:<p>Futuximab, a chimeric monoclonal antibody, targets distinct epitopes on the epidermal growth factor receptor (EGFR), exhibiting antineoplastic activity [1].</p>Pureza:95% - 95%Cor e Forma:LiquidNamilumab
CAS:<p>Namilumab (AMG203) is a humanised IgG1 monoclonal antibody that neutralises GM-CSF. rheumatoid arthritis and active axial spondyloarthritis.</p>Pureza:95%Cor e Forma:LiquidBecotatug
CAS:<p>Becotatug (JMT-101) is an IgG1 antibody that targets EGFR and can be conjugated to Afatinib and Osimertinib, functioning as a synthetic antibody-drug conjugate</p>Pureza:95% - 95%Cor e Forma:LiquidIzalontamab
CAS:<p>Izalontamab (SI-B001) is a bispecific EGFR/HER3 monoclonal antibody that binds to both EGFR×EGFR homodimers and EGFR×HER3 heterodimers.</p>Pureza:95%+ - 95%+Cor e Forma:LiquidCabiralizumab
CAS:<p>Cabiralizumab is an anti-CSF1R monoclonal antibody that enhances T cell infiltration, inhibits osteoclasts, and is used in RA and immune-oncology research.</p>Pureza:95% - 95%Cor e Forma:LiquidAnti-Mouse CD117 Antibody
<p>Anti-Mouse CD117 Antibody, a rat-derived IgG2b isotype, acts as an inhibitor specific to the mouse CD117 antigen.</p>Pureza:98%Cor e Forma:Odour SolidZalutumumab
CAS:<p>Zalutumumab is a high-affinity fully human monoclonal antibody ,the extracellular domain of the EGFR squamous cell carcinoma of the head and neck (SCCHN).</p>Pureza:95%Cor e Forma:LiquidAnbenitamab
CAS:<p>Anbenitamab (KN-026) is a bispecific HER2 antibody for metastatic breast cancer research, blocking HER2 pathways and mediating ADCC.</p>Cor e Forma:LiquidVeligrotug
CAS:<p>Veligrotug is an IV anti-IGF-1R antibody for thyroid eye disease, reducing diplopia and orbital inflammation, supporting autoimmune ophthalmopathy research.</p>Pureza:95% - 95%Cor e Forma:Liquid6-Bn-cAMP
CAS:<p>6-Bn-cAMP is a selective activator of cAMP-dependent protein kinase (PKA) that does not activate Epac. Compared to cAMP, 6-Bn-cAMP enhances hydrolytic stability against PDE, esterases, and amidases, and significantly increases membrane permeability.</p>Fórmula:C17H18N5O6PCor e Forma:SolidPeso molecular:419.33Depatuxizumab
CAS:<p>Depatuxizumab is a humanised monoclonal antibody targeting EGFR with blood-brain barrier (BBB) permeability, inhibit tumor growth,GBM,SCCHN.</p>Pureza:95%Cor e Forma:LiquidBriquilimab
CAS:<p>Briquilimab is a humanized antibody that inhibits the SCF-KIT interaction, inducing mast cell apoptosis for research into inflammatory diseases.</p>Pureza:95% - 95%Cor e Forma:LiquidFigitumumab
CAS:<p>Figitumumab is a potent anti-IGF1R mAb (IC50=1.8 nM) showing promise in advanced lung squamous cell carcinoma.</p>Pureza:95%Cor e Forma:LiquidTanezumab
CAS:<p>Tanezumab (RN-624) is a humanised monoclonal antibody targeting NGF，pain conditions, including osteoarthritis, knee arthritis, and neuropathic pain.</p>Pureza:95%Cor e Forma:LiquidFiclatuzumab
CAS:<p>Ficlatuzumab is a humanized anti-HGF mAb that inhibits c-Met signaling for squamous cell carcinoma treatment.</p>Pureza:95%Cor e Forma:LiquidZanidatamab
CAS:<p>Zanidatamab (ZW25) is a bispecific, humanized monoclonal antibody that targets two distinct epitopes (ECD2 and ECD4) of the HER2 receptor, exhibiting anti-tumor</p>Cor e Forma:LiquidImgatuzumab
CAS:<p>Imgatuzumab (RG 7160) is a humanized anti-EGFR monoclonal antibody and immunomodulator for cancer research.</p>Cor e Forma:LiquidPeso molecular:145.0 (kDa)Anti-Mouse GM-CSF Antibody (MP1-22E9)
<p>Anti-Mouse GM-CSF Antibody is a rat-derived IgG2a isotype inhibitor that targets mouse granulocyte-macrophage colony-stimulating factor (GM-CSF).</p>Pureza:98%Cor e Forma:Odour LiquidDusigitumab
CAS:<p>Dusigitumab (MEDI573) is a fully humanised monoclonal antibody targeting IGF1/IGF2, inhibiting IGF1/IGF2-induced IGF-1R phosphorylation.</p>Pureza:95% - 95%Cor e Forma:LiquidFasinumab
CAS:<p>Fasinumab (anti-NGF mAb) is in Phase III trials for acute sciatica & knee OA. It significantly improves pain & function vs. placebo.</p>Pureza:95%Cor e Forma:LiquidDovitinib Dilactic Acid
CAS:<p>Dovitinib dilactic acid: multitarget RTK inhibitor for FLT3/c-Kit (IC50=1-2 nM), FGFR1/3, VEGFR1-4 (IC50=8-13 nM), less effective on InsR, EGFR. Phase 4.</p>Fórmula:C21H21FN6O·2C3H6O3Pureza:98%Cor e Forma:SolidPeso molecular:572.59IGF-1R modulator 1
CAS:<p>IGF-1Rmodulator 1 (Example 5) is an IGF-1R modulator featuring an EC50 of 0.29 μM (FGFR1), 0.25 μM (IGF1R), 0.34 μM (TrkA), and 0.39 μM (TrkB). This compound is useful in research on diseases characterized by impaired signaling of neurotrophic and/or other trophic factors, such as Alzheimer's disease.</p>Fórmula:C22H17N3O4Cor e Forma:SolidPeso molecular:387.39Icotinib
CAS:<p>Icotinib (Conmana) is an orally available quinazoline-based inhibitor of epidermal growth factor receptor (EGFR), with potential antineoplastic activity.</p>Fórmula:C22H21N3O4Pureza:99.76% - 99.94%Cor e Forma:SolidPeso molecular:391.42CSF1R-IN-19
CAS:<p>CSF1R-IN-19 is a robust inhibitor of CSF1R that influences the exchange of inflammatory factors between TAMs and glioma cells. It holds potential for cancer research [1].</p>Fórmula:C20H27N7OCor e Forma:SolidPeso molecular:381.47S961
CAS:<p>S961: High-affinity IR antagonist; IC50: HIR-A 0.048 nM, HIR-B 0.027 nM, HIGF-IR 630 nM.</p>Fórmula:C211H297N55O71S2Pureza:98%Cor e Forma:SolidPeso molecular:4804.138-MA-cAMP
CAS:<p>8-MA-cAMP (8-Methylamino-cAMP) is a cyclic adenosine monophosphate analog that acts as a site-selective PKA agonist, exhibiting similar affinity for the B site of both Type I and Type II protein kinase A. When used in conjunction with analogs that preferentially target site A, such as 8-piperidinyl cAMP, 8-MA-cAMP facilitates selective stimulation of Type I enzymes.</p>Fórmula:C11H15N6O6PCor e Forma:SolidPeso molecular:358.25lavendustin A
CAS:<p>lavendustin A (RG-14355) is a potent, cell-permeable inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase.</p>Fórmula:C21H19NO6Pureza:98%Cor e Forma:Off-White SolidPeso molecular:381.388-Chloro-cAMP sodium
CAS:<p>8-Chloro-cAMP sodium is a cAMP analog that induces growth arrest and modulates cAMP-dependent PKA activity. This compound also exhibits anticancer activity.</p>Fórmula:C10H10ClN5NaO6PCor e Forma:SolidPeso molecular:385.63ZM323881 hydrochloride
CAS:<p>ZM323881 hydrochloride (ZM 323881 HCl) is a potent and selective VEGFR2 inhibitor.</p>Fórmula:C22H19ClFN3O2Pureza:99.43%Cor e Forma:SolidPeso molecular:411.86BMS-754807
CAS:<p>BMS-754807 is an oral IGF-1R/InsR inhibitor with potential anti-cancer properties.</p>Fórmula:C23H24FN9OPureza:99.69% - 99.94%Cor e Forma:SolidPeso molecular:461.49Icotinib Hydrochloride
CAS:<p>Icotinib Hydrochloride, an oral EGFR inhibitor (BPI-2009H), may halt cancer growth by blocking EGFR signaling.</p>Fórmula:C22H22ClN3O4Pureza:99.89%Cor e Forma:SolidPeso molecular:427.88TAK-285
CAS:<p>TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc.</p>Fórmula:C26H25ClF3N5O3Pureza:99.73%Cor e Forma:SolidPeso molecular:547.96CP-547632
CAS:<p>CP-547632 is an oral ATP-competitive inhibitor of VEGFR-2/FGF kinase with IC50s of 11/9 nM, highly selective, has antitumor activity.</p>Fórmula:C20H24BrF2N5O3SPureza:99.39%Cor e Forma:SolidPeso molecular:532.4GW843682X
CAS:<p>GW843682X (GW843682) is a selective and ATP-competitive inhibitor of PLK1 and PLK3 (IC50s = 2.2 nM and 9.1 nM).</p>Fórmula:C22H18F3N3O4SPureza:99.92%Cor e Forma:SolidPeso molecular:477.46AMG-458
CAS:<p>AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.</p>Fórmula:C30H29N5O5Pureza:99.91% - 99.98%Cor e Forma:SolidPeso molecular:539.58EGFR-IN-53
CAS:<p>EGFR-IN-53 (Compound 7) is a potent inhibitor of EGFR (IC50 = 8.264 μM) that exhibits cytotoxic activity against cancer cell lines [1].</p>Fórmula:C14H13N3O2SCor e Forma:SolidPeso molecular:287.34CAY10717
CAS:<p>CAY10717 inhibits 34/104 kinases at 100 nM, targets EGFR/ABL/B-Raf mutations, kills various cancer cells, and blocks HUVEC growth.</p>Fórmula:C29H25F3N6O3Cor e Forma:SolidPeso molecular:562.54DDR-TRK-1
CAS:<p>DDR-TRK-1 is a selective discoid domain receptor 1 (DDR1) inhibitor with IC50 value of 9.4 nM. DDR-TRK-1 also inhibits the TRK family.</p>Fórmula:C26H23F3N6OPureza:99.63%Cor e Forma:SolidPeso molecular:492.5Gilteritinib hemifumarate
CAS:<p>Gilteritinib hemifumarate (ASP2215 hemifumarate) is a potent ATP-competitive dual FLT3 (IC50: 0.29 nM) and AXL (IC50: 0.73 nM) inhibitor for the treatment of</p>Fórmula:C29H44N8O3C4H4O4Pureza:99.78%Cor e Forma:SolidPeso molecular:610.75Gefitinib N-oxide
CAS:<p>Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib N-oxide is the N-oxide derivative of Gefitinib.</p>Fórmula:C22H24ClFN4O4Pureza:98%Cor e Forma:SolidPeso molecular:462.9Glesatinib
CAS:Glesatinib is an orally active and potent dual inhibitor of MET/SMO.Fórmula:C31H27F2N5O3S2Pureza:98%Cor e Forma:SolidPeso molecular:619.7
